PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+18.83%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$2.67B
AUM Growth
+$2.67B
(-5.5%)
Cap. Flow
-$524M
Cap. Flow
% of AUM
-19.65%
Top 10 Holdings %
Top 10 Hldgs %
54.89%
Holding
105
New
17
Increased
12
Reduced
35
Closed
21
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$166M |
| 2 |
OMDA
Omada Health, Inc. Common Stock
OMDA
|
$44.4M |
| 3 |
Roivant Sciences
ROIV
|
$37.5M |
| 4 |
CAI
Caris Life Sciences, Inc. Common Stock
CAI
|
$29.3M |
| 5 |
Neurocrine Biosciences
NBIX
|
$19.5M |
Top Sells
| 1 |
Lyra Therapeutics
LYRA
|
$112M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$104M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$99.9M |
| 4 |
Soleno Therapeutics
SLNO
|
$90.2M |
| 5 |
Amicus Therapeutics
FOLD
|
$80.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CAI
26
Caris Life Sciences, Inc. Common Stock
CAI
$10.6B
| $29.3M | 1.09% |
+1,098,163
| New | +$29.3M |
|
27
Intuitive Surgical
ISRG
$169B
| $24.5M | 0.91% |
45,119
+4,500
| +11% | +$2.45M |
|
28
ADMA Biologics
ADMA
$4.06B
| $23.7M | 0.88% |
1,303,468
-69,765
| -5% | -$1.27M |
|
|
BBNX
29
Beta Bionics, Inc. Common Stock
BBNX
$823M
| $23.2M | 0.86% |
1,593,608
| – | – |
|
30
Spyre Therapeutics
SYRE
$1.01B
| $22.9M | 0.85% |
1,529,445
-783,827
| -34% | -$11.7M |
|
31
Evolus
EOLS
$492M
| $22.8M | 0.85% |
2,474,843
-1,654,299
| -40% | -$15.2M |
|
32
Celcuity
CELC
$2.22B
| $21.8M | 0.81% |
1,633,208
-729,071
| -31% | -$9.73M |
|
33
Dyne Therapeutics
DYN
$1.94B
| $21.4M | 0.79% |
2,247,390
-66,013
| -3% | -$628K |
|
|
SION
34
Sionna Therapeutics, Inc. Common Stock
SION
$1.11B
| $21.1M | 0.78% |
1,216,045
-35,056
| -3% | -$608K |
|
35
Axsome Therapeutics
AXSM
$6.21B
| $20.7M | 0.77% |
198,534
-156,573
| -44% | -$16.3M |
|
36
Repligen
RGEN
$6.85B
| $20.6M | 0.77% |
166,000
+36,199
| +28% | +$4.5M |
|
37
Insulet
PODD
$24.2B
| $19M | 0.7% |
60,387
-11,210
| -16% | -$3.52M |
|
38
Outset Medical
OM
$245M
| $16M | 0.59% |
833,333
| – | – |
|
39
Zymeworks
ZYME
$1.1B
| $16M | 0.59% |
1,275,274
-589,398
| -32% | -$7.4M |
|
40
CytomX Therapeutics
CTMX
$343M
| $15.9M | 0.59% |
+6,993,646
| New | +$15.9M |
|
41
Aldeyra Therapeutics
ALDX
$352M
| $15.5M | 0.58% |
4,051,631
-5,224,220
| -56% | -$20M |
|
42
Charles River Laboratories
CRL
$7.97B
| $15.2M | 0.56% |
+100,000
| New | +$15.2M |
|
|
CNTA
43
Centessa Pharmaceuticals
CNTA
$2.3B
| $15.1M | 0.56% |
1,146,935
-1,893,460
| -62% | -$24.9M |
|
44
Inhibrx
INBX
$405M
| $14M | 0.52% |
977,892
-86,134
| -8% | -$1.23M |
|
|
ADGM
45
Adagio Medical Holdings, Inc Common Stock
ADGM
$24.1M
| $12.8M | 0.48% |
9,876,576
+64,157
| +0.7% | +$83.4K |
|
46
Nurix Therapeutics
NRIX
$732M
| $12.5M | 0.46% |
1,096,985
+799,432
| +269% | +$9.11M |
|
47
Travere Therapeutics
TVTX
$1.64B
| $12.3M | 0.46% |
+834,252
| New | +$12.3M |
|
48
Orchestra BioMed
OBIO
$148M
| $12.3M | 0.46% |
4,592,556
| – | – |
|
|
DRUG
49
Bright Minds Biosciences
DRUG
$271M
| $11M | 0.41% |
420,690
-23,959
| -5% | -$626K |
|
50
Inhibikase Therapeutics
IKT
$136M
| $10.6M | 0.39% |
5,432,293
-492,707
| -8% | -$961K |
|